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The highly porous and robust [Ni8(OH)4(OH2)2(4,4
0-(buta-1,3-
diyne-1,4-diyl)bispyrazolato)6]n MOF can be used as a proof
of concept for the incorporation and release of the non-
conventional [Ru(p-cymene)Cl2(pta)] RAPTA-C metallodrug.
In the last few years, the interest in the outperforming
adsorptive properties of Metal–Organic Frameworks (MOFs)
has been extended from an initial focus on gas storage and
puriﬁcation to the controlled release of bioactive molecules.1
Depending on pore nature and size, the bioactive species to be
delivered can range from small gaseous molecules (e.g. NO,
CO) coordinated to the open metal sites,2 to small organic
drugs (ibuprofen,3 doxorubicin)4,5 physisorbed in the pore
structure, or even to metalloligand pro-drugs used as linkers
within the MOF itself.6
One of the current major social concerns is to ﬁnd eﬀective
treatments to cure cancer. It is well known that the use of
Pt(II)-based cytotoxic metallodrugs is one of the most widespread
treatments against cancer.7 However, the adverse side eﬀects
and the development of resistance are related to the unspeciﬁc
interactions of Pt(II) metallodrugs with biomolecules, in particular
with the desired biological target, DNA.
Consequently, there is much interest in ﬁnding new metallo-
drugs with a diﬀerent mechanism of action. A number of half-
sandwich type organometallic compounds of Ru, Rh, Ir and
Os have emerged as alternative anti-tumour and anti-
metastatic metallodrugs, exhibiting a diﬀerent mechanism of
action that may lead to fewer adverse side eﬀects. Indeed, it
seems that the primary activity of these species does not
involve DNA but the inhibition of the exacerbated metabolism
of many cancer cell types (i.e. inhibition of over-expressed
enzymes like cathepsines),8 or the interference with physiological
redox processes.9 In this sense, a notable example is the non-
conventional metallodrug [Ru(p-cymene)Cl2(pta)] (pta =
1,3,5-triaza-7-phospha-adamantane), termed ‘‘RAPTA-C’’
(Fig. 1), which is proved to inhibit lung metastases in mice.10
Accordingly, it would be highly beneﬁcial for patients to ﬁnd
methods for the controlled delivery of these novel metallodrugs.
In this communication, we present the synthesis and full
characterisation of the highly porous and robust [Ni8(m4-OH)4-
(m4-OH2)2(m4-4,4 0-(buta-1,3-diyne-1,4-diyl)bispyrazolato)6]n
(1) MOF containing a new bispyrazolate type organic linker.
Worthy of note, 1 shows a remarkable thermal and chemical
stability, even in simulated body ﬂuid (SBF).11 Moreover, we
have studied the incorporation and release of RAPTA-C in 1
as a proof of concept of the utility of MOFs for the delivery of
this type of non-conventional metallodrugs.
The key step of the synthesis of the novel organic linker
adopted in this study was a Pd/Cu-catalyzed homocoupling
reaction on the boc-protected 4-ethynyl-pyrazole precursor to
achieve the symmetric rod-like species 1,10-di-Boc-4,40-(buta-
1,3-diyne-1,4-diyl)bispyrazole (Fig. 1). The posterior reaction
of this system with Ni(AcO)24H2O in boiling aqueous DMF
gave rise to the deprotection of the pyrazolate donor groups,
Fig. 1 (a) The 4,40-(buta-1,3-diyne-1,4-diyl)bispyrazole linker used in
this study; (b) the anti-tumour metallodrug [Ru(p-cymene)Cl2(pta)]
(pta = 1,3,5-triaza-7-phospha-adamantane), RAPTA-C, used in the
drug delivery process.
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An XRPD structural analysis demonstrated that 1H2O
DMF is isomorphous to the [Ni8(m4-OH)4(m4-OH2)2
(m4-L)6]nnSolv systems previously reported by us.12 Accordingly,
the structure of 1H2ODMF is based on Ni8(OH)4(OH2)2
cubic clusters connected to 12 adjacent ones by linear exo-
tetradentate N,N,N0,N0 4,40-(buta-1,3-diyne-1,4-diyl)bispyra-
zolato linkers. Noteworthily, this topology, reminiscent of
the cubic close packing structure found in many elemental
solids, features octahedral and tetrahedral voids of about
1.6 nm and 1.0 nm inner size13 respectively (Fig. 2). As a
consequence of the large voids and the low steric demand of
the diyne residues in the organic linker, the calculated acces-
sible pore volume in the structure is very high, reaching 71%
of the total crystal volume.
The thermogravimetric analysis carried out in air on 1H2O
DMF and on the CH2Cl2 exchanged material 1CH2Cl2
(Fig. S2, ESIw) shows that, upon removal of the guest solvent
molecules, the evacuated structure remains stable up to 340 1C,
the temperature after which it undergoes a rapid decomposition.
Moreover, 1 also shows a high mechanical stability, its crystal-
linity and porosity remaining almost unaﬀected when pressed up
to 2 Mg cm2 (Fig. S4, ESIw).
N2 adsorption experiments carried out on 1 at 77 K are indicative
of a highly porous structure exhibiting a type I isotherm typical of
crystalline microporous materials (Fig. 3). The BET surface area of
1920 m2 g1 is remarkably high, as it is the adsorption capacity,
which reaches the value of 26 mmol g1 at p/po = 0.3.
Noteworthily, 1 also possesses a remarkably high chemical
stability, which is exempliﬁed by the fact that its XRPD
remains unaltered up to 24 h in boiling water and in common
organic solvents, in basic (NaOH 0.05 M, pH 12.80) and acidic
(HCl 0.01 M, pH 2.30) aqueous solutions, as well as in
simulated body ﬂuid (SBF) at 37 1C (pH 8.05) for 7 days
(Fig. S3, ESIw). The robustness of this material in SBF is
proved by means of atomic absorption (AA) measurements,
indicating very low Ni leaching. Indeed, suspensions of 1 in
SBF at 37 1C (20 mg of 1 in 40 mL of SBF) give rise to 0.7 ppm
of Ni concentration levels, which indicate that only 0.43% of
the MOF material has been degraded. This value corresponds
to the liberation of 70 mg of Ni per 100 mL of SBF with
suspended 1. It should be noted that this amount is neatly
below the daily average uptake of 170 mg of Ni in food.14
The stability of 1 under simulated biological conditions, the
pore size and non-charged nature of the framework prompted us
to explore the possible incorporation and posterior release of the
non-conventional RAPTA-Cmetallodrug (estimated diameter of
0.9 nm)15 in its porous structure. Indeed, impregnation of 1 with
an aqueous solution of RAPTA-C (0.025 M) leads to the rapid
incorporation of this metallodrug, the equilibrium being reached
after 4 h. The dramatic decrease in N2 uptake capacity after
RAPTA-C loading (Fig. 3) with maintenance of the structural
integrity as evidenced by XRPD can be taken as a proof of the
occupancy of the cavities by the drug (see ESIw).
After this initial proof of RAPTA-C incorporation, we have
studied more in detail the solid–liquid adsorption process at
298 K. The results show a type I adsorption isotherm (Fig. 4),
whose data-points have been satisfactorily ﬁtted to the linear
form of the Langmuir model (eqn (1)):
C/n = C/nm + 1/(Knm) (1)
where C is the concentration of RAPTA-C in the aqueous
solution (M) at the equilibrium, n is the amount of RAPTA-C
incorporated in 1 (mmol g1), K is the Langmuir equilibrium
constant and nm corresponds to the predicted saturation
loading of RAPTA-C in 1 (mmol g1). The results show a
maximum loading nm value of 2.4 mmol (1.1 g) of RAPTA-C
per gram of 1. Noteworthily, this high loading value corre-
sponds to four RAPTA-C molecules per MOF formula unit.
Taking into account the inner size (ca. 1.6 and 1.0 nm,
respectively) of the octahedral and tetrahedral voids in 1, as
well as the size of the RAPTA-C molecule (0.9 nm), we can
tentatively conclude that the octahedral and tetrahedral
Fig. 2 View of the crystal structure of [Ni8(m4-OH)4(m4-OH2)2-
(m4-4,40-(buta-1,3-diyne-1,4-diyl)bispyrazolato)6]n (1) along the [100]
direction and the magniﬁed view of the 12-connecting Ni8(m4-OH)4-
(m4-OH2)2 nodes (above); view of the octahedral and tetrahedral voids
found in the crystal structure of 1 (below). Ni: green, O: red, N: blue,
C: grey, H: light grey.
Fig. 3 N2 (77 K) adsorption isotherms for activated [Ni8(m4-OH)4-
(m4-OH2)2(m4-4,40-(buta-1,3-diyne-1,4-diyl)bispyrazolato)6]n (1) (blue
triangles) and the RAPTA-C loaded 1RAPTA-C product (orange
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cavities, present in a 1 : 2 ratio, host two and one RAPTA-C
molecules each, respectively, to give rise to 1RAPTA-C.
Finally, we have studied the desorption process of the
loaded 1RAPTA-C into SBF at 37 1C, in order to test the
use of this system as a model for drug delivery purposes. The
results show that the equilibrium of RAPTA-C release from 1
RAPTA-C is reached after 5 hours.16 The desorption data can
be satisfactorily ﬁtted with a ﬁrst order kinetic model according
to eqn (2):
qE  qt = qE ekt (2)
where qE and qt are the amounts of RAPTA-C released per
gram of MOF (mmol g1) at the equilibrium and at the time
t (h), respectively, and k is the ﬁrst order kinetic constant (h1).
The ﬁtting of the data gives rise to a k value of 1.63 h1 which
corresponds to a t1/2 for the release of the metallodrug, of
25 min (Fig. 5). This is indicative of the physisorption of the
metallodrug in 1, ruling out its chemical binding, through
ligand exchange reactions, to the extended p-system of diynes
provided by the MOF itself. The reversibility of the adsorption
process can be further stated by quantifying the amount of
released drug after the equilibrium is reached (desorption
branch of solid–liquid isotherm at 37 1C). The results show
that, when 10 mg of 1RAPTA-C are suspended in 20 mL of
SBF, 20% of the hosted metallodrug is released leading to a
0.1 mM RAPTA-C solution. Noteworthily, the released
amount at the equilibrium increases to 70% when the SBF
volume is enlarged to 200 mL, which corresponds to a 0.004 mM
RAPTA-C solution.
In conclusion, we have obtained a novel highly porous MOF
with a remarkably high thermal, mechanical and chemical
stability. These features make it a model for drug delivery purposes
via oral administration or transdermal patches, as demonstrated by
the loading of a signiﬁcant quantity of the unconventional metallo-
drug RAPTA-C, namely 1.1 g of drug per gram of MOF.
Noteworthily, the adsorption process is reversible as a consequence
of physisorption, RAPTA-C being easily released into simulated
body ﬂuid. All these features concur in making 1 an outstanding
proof of concept for the suitability of MOFs as releasing systems
for this type of non-conventional metallodrugs. Work can be
anticipated in extending these intriguing results to novel MOFs
based on metal ions with lower toxicity.
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